STOCK TITAN
  1. Home
  2. News
  3. LIXT

Lixte Biotechnology Holdings, Inc. - $LIXT STOCK NEWS

Welcome to our dedicated page for Lixte Biotechnology Holdings news (Ticker: $LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lixte Biotechnology Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lixte Biotechnology Holdings's position in the market.

News
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
Rhea-AI Summary
LIXTE Biotechnology Holdings, Inc. has entered into a securities purchase agreement with a healthcare-focused institutional investor. The agreement involves the purchase and sale of 583,334 shares of common stock and common warrants to purchase up to 583,334 shares of common stock. The purchase price is $6.00 per common share, and the exercise price for the warrants is also $6.00 per share. The closing of the offering is expected to occur on or about July 20, 2023, with gross proceeds of approximately $3,500,000. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.47%
Tags
offering
-
News
Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
Rhea-AI Summary
LIXTE Biotechnology announces that inhibiting PP2A with LB-100 sensitizes cancer cells to immunotherapy and chemotherapy. This mechanism turns 'cold' tumors 'hot' and enhances the effectiveness of checkpoint blockade antibodies. LB-100 also disrupts mRNA maturation, reducing cancer cells' ability to deal with DNA damage. Collaboration with the Netherlands Cancer Institute led to these findings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.67%
Tags
clinical trial
-
News
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
none
News
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.45%
Tags
clinical trial
-
News
LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
News
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
none
News
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
clinical trial
-
News
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
clinical trial
-
News
LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.28%
Tags
clinical trial
News
LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
133.33%
Tags
none
Stock LIXT logo
Lixte Biotechnology Holdings, Inc.

Nasdaq:LIXT

LIXT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

LIXT Stock Data

6.50M
1.98M
20.48%
5.08%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
EAST SETAUKET

About LIXT

lixte biotechnology holdings, inc. (lixte) is a clinical-stage public (lixt) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. the current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and dna damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. the phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. the lead compound lb-100 is in phase i trial and has the potential to be first-in-class. the deacetylase in